Amgen and Teva Pharmaceuticals Industries have been granted permission for an expedited appeal in an antitrust case related to Amgen’s Sensipar, a calcium reducer, after a lower court decision.
According to a memorandum by Judge Colm F. Connolly in the US District Court for the District of Delaware, pharmaceutical companies have the right to appeal a decision if he finds that he does not have the authority to allow an interlocutory appeal of a previous judge’s ruling.
Related: Warren Sends Letter To FTC Over Amgen & Indivior Deals
There is “substantial ground for difference of opinion” about whether a judge can certify for interlocutory appeal another judge’s order in the same case, Connolly said.
Featured News
Judge Mehta Questions Both Sides in Landmark Google Antitrust Case
May 2, 2024 by
CPI
FCC Urges Urgent Funding for Removal of Chinese Telecom Equipment from U.S. Networks
May 2, 2024 by
CPI
Former Pioneer CEO Facing Potential Criminal Charges For Colluding With OPEC
May 2, 2024 by
CPI
South Korea’s Antitrust Regulator Greenlights K-Pop Powerhouse Deal
May 2, 2024 by
CPI
Exxon’s Pioneer Purchase Approved, Former CEO Barred from Board
May 2, 2024 by
CPI
Antitrust Mix by CPI
Antitrust Chronicle® – Economics of Criminal Antitrust
Apr 19, 2024 by
CPI
Navigating Economic Expert Work in Criminal Antitrust Litigation
Apr 19, 2024 by
CPI
The Increased Importance of Economics in Cartel Cases
Apr 19, 2024 by
CPI
A Law and Economics Analysis of the Antitrust Treatment of Physician Collective Price Agreements
Apr 19, 2024 by
CPI
Information Exchange In Criminal Antitrust Cases: How Economic Testimony Can Tip The Scales
Apr 19, 2024 by
CPI